RayzeBio, Inc.

RayzeBio, Inc. headquartered in San Diego, California, was founded to develop a line of radiopharmaceuticals for the treatment of various types of solid tumors.

The company's lead product, RYZ101, is entering Phase 3 trials for the treatment of gastroenteropancreatic neuroendocrine tumors. Any positive news on these trials could lead to very strong gains for this stock.

The global solid tumor treatment market is projected to reach $532 billion by 2032, driving growth for companies in this sector.
_________________________________
Number of employees:
50 - 100
_________________________________
Headquarters:
5505 Morehouse Drive, Suite 300 San Diego, CA 92121